Linognathus setosus (L. setosus) is a dog louse that causes dermatological signs. Currently, there is a transdermal combination for the control of enteroparasites and ectoparasites (imidacloprid / moxidectin / praziquantel). However, has not been labeled for lice. Therefore, the aim of the study was to evaluate the efficacy of imidacloprid / moxidectin / praziquantel. Five dogs were used; three females and two males of the following breeds: boxer, pitbull, schnauzer, and mongrel. A dermatological examination and hair microscopy, as well as microscopic examination of feces (direct and by sedimentation), were performed on days 1, 7, and 28. Nymphs and adult lice on the shoulder, neck, back and head were counted at first sight and confirmed by optical microscope. Dermatological lesions were evaluated with the classification: 0, healthy skin, 1, mild, 2, moderate, and 3, severe. Pruritus was evaluated with the visual analog scale (PVAS). On day 1 of the evaluation, all animals were treated with imidacloprid (10–35 mg/kg), moxidectin (2.5 mg/kg) and praziquantel (25–50 mg/kg). Five dogs were positive for L. setosus and 4 of them for Dipylidium caninum. On day 1, they presented lesions level 3 and pruritus 8. On day 7 of evaluation, they were negative for L. setosus and Dipylidium caninum, the lesions were 1 for four dogs and 2 for one, by day 28 of evaluation, all continued negative to L. setosus and Dipylidium caninum. The transdermal application of imidacloprid / moxidectin / praziquantel is effective for the control of L. setosus and Dipylidium without showing adverse effects.

We investigated the incidence of adverse reactions to Cephalexin, Minocycline and Fosfomycin in 437 dogs which were diagnosed with pyoderma at the TRVA Secondary Medical Center Dermatology Department and Dog and Cat Dermatology Department from November 2014 to October 2022. The incidence of adverse reactions was 8.5% (13/153) for Cephalexin, 21.0% (21/100) for Minocycline, and 16.3% (30/184) for Fosfomycin. The incidences of adverse reactions to Minocycline and Fosfomycin were higher than that of Cephalexin. There were also statistically significant differences in adverse reactions between Cephalexin and both Minocycline and Fosfomycin. The adverse reactions to Cephalexin were soft stool and diarrhea (53.8%), vomiting (46.2%), and anorexia (7.7%); the adverse reactions to Minocyclne were soft stool and diarrhea (33.3%), vomiting (66.7%), and anorexia (28.6%); and the adverse reactions to Fosfomycine were loose stools and diarrhea (86.7%), vomiting (26.7%), and anorexia (3.3%). In cases where follow-up was possible, the onset of adverse reactions was within a week in 75.0% of cases, and within 2 weeks for all cases. In 43.8% of cases, dosing was continued without treatment for adverse reactions; in 12.5% of cases, dosing was continued with treatment for adverse reactions; and in 43.8% of cases, adverse reactions improved after stopping the medication. None of the adverse reactions persisted after suspension of medication and none required symptomatic treatment. Age, breed, comorbidities and prescription drugs were not found to be involved in this study.